BRCA Test to Dominate the Global Breast Cancer Diagnostics Market Through 2022 | Abbott Laboratories, Roche Holding AG, Thermo Fischer Scientific

According to a recent study by Fact.MR, the global breast cancer diagnostics market is projected to register a moderate CAGR of 4.7% during the forecast period 2017 to 2022.

Click here to Get Complete Synopsis of the Report – https://www.factmr.com/report/55/breast-cancer-diagnostics-market

The report estimates the market to surpass US$ 2,000 Mn in revenues by 2022-end.

In diagnostic platforms of breast cancer, a number of technological advancements have led towards a robust transformation of the global breast cancer diagnostics market. The emergence of hybrid diagnostics instruments with the provision of an enhanced accuracy have been witnessed in the market. Advancements such as these have been fuelling growth of the global market for breast cancer diagnostics.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=55

Surging cases of breast cancer, coupled with growing older women population are anticipated to create potential growth opportunities for breast cancer diagnostics market across the globe. However, lack of skilled as well as trained personnel is expected to inhibit the demand for breast cancer diagnostics during the forecast period.

The most common type of cancer for women across the globe currently is breast cancer. The number of breast cancer cases is expected to witness a rise, leading towards the requirement for efficient and early breast cancer detection. An established method, mammography, adopted in many countries, has recently been observed to provide inconclusive test results.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=55

Personalized and risk-adapted therapy are expected to resolve these difficulties. Tomosythesis, which has emerged as a new imaging technology, promises to overcome the challenges incurred in mammography.

8 Estimations for the Global Breast Cancer Diagnostics Market

• By test type, BRCA will remain dominant in the global breast cancer diagnostics market.
• CA test for diagnostics of breast cancer is expected to register the highest CAGR through 2022 in the market, followed by ER & PR. Revenue from ER & PR, and CA tests will continue to be low throughout the forecast period.

For in-depth competitive analysis, buy now - https://www.factmr.com/checkout/55/S

• HER 2 test is expected to remain the second largest segment among test type, in the market. However, EGFR mutation test is estimated to account for low revenues in the global market for breast cancer diagnostics.
• North America will continue to be the largest market for breast cancer diagnostics. Revenues from breast cancer diagnostics market in North America is estimated to surpass US$ 800 Mn by 2022-end.
• Europe will remain the second most lucrative region for the breast cancer diagnostics market. However, markets in Japan, and Middle East & Africa (MEA) are anticipated to witness a sluggish expansion throughout the forecast period.
• Hospital-associated labs will remain sought-after among end-users for breast cancer diagnostics around the world. Revenues from breast cancer diagnostics will remain largest in hospital-associated labs, followed by the independent diagnostic laboratories.

For comprehensive insights on this market adoption, ask an analyst here - https://www.factmr.com/connectus/sample?flag=AE&rep_id=55

• Cancer research institutes are anticipated to exhibit the highest CAGR during the forecast period. Between 2017 and 2022, cancer research institutes are estimated to create absolute $ opportunity of US$ 107.3 Mn.
• Key market players mentioned in Fact.MR’s report include Siemens AG, Myriad Genetics, Inc., Roche Holding AG, Illumina, Inc., Epigenomics AG, Abbott Laboratories, Thermo Fischer Scientific, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., AstraZeneca plc, and Quest Diagnostics Incorporated.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Research Insight: https://www.factmr.com/report/55/breast-cancer-diagnostics-market
Content Source: https://www.factmr.com/media-release/41/breast-cancer-diagnostics-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.